Influenza virus hemagglutinin and matrix protein 2 (HA/M2)

Influenza virus hemagglutinin (HA) and matrix protein 2 (M2) are critical structural proteins of the influenza virus that serve as primary targets for the host immune system and pharmacological intervention. HA is a surface glycoprotein responsible for binding to host cell sialic acid receptors and facilitating membrane fusion, making it the primary component of seasonal vaccines (Skehel & Wiley, 2000, Annual Review of Biochemistry). M2 is a proton-selective ion channel essential for the acidification of the viral interior during uncoating and for viral progeny assembly (Pinto et al., 1992, Cell). While HA is highly prone to antigenic drift, the extracellular domain of M2 (M2e) is highly conserved, leading to its investigation as a component of universal influenza vaccines (Pardi et al., 2018, Nature Reviews Drug Discovery). Therapeutic strategies targeting these proteins include small molecule inhibitors that block ion channel activity or fusion, as well as vaccine-encoded antigens designed to elicit neutralizing antibodies and T-cell responses (Wang et al., 2013, Journal of Virology). The immune-mediated recognition of these vaccine-encoded antigens is the cornerstone of modern prophylactic strategies against influenza infection. Monitoring efficacy typically involves measuring antibody titers against HA or M2e to ensure robust protection across different viral strains.

Other names

HemagglutininMatrix protein 2M2 ion channelHAM2M2eInfluenza A virus surface glycoprotein

Hemagglutinin inhibitors prevent viral attachment to host cells and membrane fusion, while Matrix protein 2 inhibitors block the proton channel required for viral uncoating; vaccines induce immune recognition of these antigens to neutralize the virus.